Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVXFree Report) by 2.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,632 shares of the company’s stock after selling 524 shares during the period. Principal Financial Group Inc.’s holdings in Vaxcyte were worth $1,103,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. RA Capital Management L.P. increased its position in Vaxcyte by 8.2% during the second quarter. RA Capital Management L.P. now owns 7,891,254 shares of the company’s stock worth $394,089,000 after buying an additional 600,000 shares in the last quarter. BlackRock Inc. increased its position in Vaxcyte by 39.0% during the second quarter. BlackRock Inc. now owns 7,065,088 shares of the company’s stock worth $352,830,000 after buying an additional 1,983,223 shares in the last quarter. Vanguard Group Inc. increased its position in Vaxcyte by 12.5% during the third quarter. Vanguard Group Inc. now owns 4,452,145 shares of the company’s stock worth $106,851,000 after buying an additional 496,227 shares in the last quarter. Capital Research Global Investors increased its position in Vaxcyte by 17.9% during the second quarter. Capital Research Global Investors now owns 3,364,127 shares of the company’s stock worth $168,005,000 after buying an additional 511,121 shares in the last quarter. Finally, State Street Corp increased its position in Vaxcyte by 2.8% during the second quarter. State Street Corp now owns 3,163,312 shares of the company’s stock worth $157,976,000 after buying an additional 87,296 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Mizuho assumed coverage on Vaxcyte in a research report on Thursday, December 7th. They issued a “buy” rating and a $69.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Vaxcyte in a research report on Tuesday, November 7th. Finally, Bank of America lifted their price objective on Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte presently has a consensus rating of “Buy” and an average price target of $68.40.

Get Our Latest Research Report on Vaxcyte

Insider Activity at Vaxcyte

In related news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Friday, November 24th. The stock was sold at an average price of $49.09, for a total value of $736,350.00. Following the transaction, the chief executive officer now owns 370,914 shares in the company, valued at $18,208,168.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Friday, November 24th. The stock was sold at an average price of $49.09, for a total value of $736,350.00. Following the transaction, the chief executive officer now owns 370,914 shares in the company, valued at $18,208,168.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mikhail Eydelman sold 10,000 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $56.50, for a total value of $565,000.00. Following the transaction, the senior vice president now owns 21,035 shares in the company, valued at approximately $1,188,477.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 145,566 shares of company stock worth $9,002,817. 3.60% of the stock is owned by insiders.

Vaxcyte Trading Up 0.9 %

Shares of Vaxcyte stock opened at $74.81 on Friday. Vaxcyte, Inc. has a twelve month low of $34.11 and a twelve month high of $76.72. The stock has a market capitalization of $7.12 billion, a P/E ratio of -22.40 and a beta of 0.93. The business’s fifty day moving average price is $63.18 and its 200 day moving average price is $54.21.

About Vaxcyte

(Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Featured Articles

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVXFree Report).

Institutional Ownership by Quarter for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.